key: cord-0745421-oqxjb4ef
authors: González Rodríguez, Paz; Pérez-Moneo Agapito, Begoña; AlbiRodríguez, María Salomé; Aizpurua Galdeano, Pilar; Aparicio Rodrigo, María; Fernández Rodríguez, María Mercedes; Esparza Olcina, María Jesús; Ochoa Sangrador, Carlos
title: COVID-19: Critical appraisal of the evidence
date: 2021-07-23
journal: An Pediatr (Engl Ed)
DOI: 10.1016/j.anpede.2021.05.003
sha: 41178c5947cb1b77783e19c58f998acd8bc0b5f4
doc_id: 745421
cord_uid: oqxjb4ef

We present the summary of a critical appraisal document of the available evidence on COVID-19, developed with a clinical practice guide format following GRADE methodology. The document tries to provide answers to a series of structured clinical questions, with an explicit definition of the population, intervention / exposure, comparison and outcome, and a rating of the clinical relevance of the outcome measures. We conducted a systematic review of the literature to answer the questions, grouped into six chapters: epidemiology, clinical practice, diagnosis, treatment, prevention, and vaccination. We assessed the risk of bias of the selected studies with standard instruments (RoB-2, ROBINS-I, QUADAS and Newcastle-Ottawa). We constructed evidence tables and, when necessary and possible, meta-analysis of the of the most relevant outcome measures. We followed the GRADE system to synthesize the evidence, assessing its quality, and, when appropriate, giving recommendations, rated according to the quality of the evidence, the values and preferences, the balance between benefits, risks and costs, equity and feasibility.

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is having an enormous impact worldwide, and especially in Spain. It poses a challenge to our health care system, with important health, social and economic repercussions due to the impact on the way of life that results from the fight against the disease and the associated morbidity and mortality.

There is a growing body of evidence on coronavirus disease 2019 (COVID- 19) , with initial research conducted on an urgent basis and under exceptional circumstances, which led to the publication of studies with significant limitations. The accrued evidence has acquired an astonishing magnitude in its volume, immediacy and, increasingly, its quality and collaborative nature. The analysis of the research published to date is not only a challenge in terms of quantity, but also in terms of quality, as it requires identifying which studies are valid and which results applicable.

The paediatric population has not been as affected as other age groups, as most infections in this group have been mild or asymptomatic, with few patients developing potentially severe forms of disease. Consequently, a large part of the available data, from both observational and, especially, experimental studies, has focused on the adult population. This is the body of evidence in which we have to search for answers to most of the questions paediatricians have about the infection.

Given the circumstances, the Committee on Evidence-Based Paediatrics of the Asociación Española de Pediatría (Spanish Association of Pediatrics, AEP) and the Asociación Española de Pediatría de Atención Primaria (Spanish Association of Primary Care Paediatrics, AEPap) felt the need to develop a document on the current evidence on the subject of COVID-19 in the paediatric population (0-18 years), addressing every aspect of the disease: epidemiology, clinical characteristics, diagnosis, treatment, prevention and vaccination.

To search, evaluate, synthesise and establish the relative importance of the available evidence and to develop recommendations based on this evidence is a challenge: it requires that we navigate uncertainty and handle a substantial amount of information, in large part indirect. Our aim was to offer a summary of the evidence published to date accompanied by an assessment of its quality, information that must provide the foundation for clinical decision-making, adapted to the circumstances of each patient. Our intent was not to provide directions to be applied as presented, and this document should not be interpreted as a protocol; instead, we aimed to provide information with which to form the necessary judgments to optimise the management of paediatric patients. This information must be combined with clinical experience and expert opinion to develop the protocols demanded by our health care system and society at large.

To develop this document, we have adhered in part to the methodology manual for the development of clinical practice guidelines of the public health system of Spain. 1 We assessed the quality of the evidence and established the strength of recommendations applying the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. 2 The full document provides a detailed description of the methods used. 3 In short, the steps were as follows: 1) formulation of structured clinical questions to address 2) performance of systematic literature searches, with updates on an ongoing basis; 3) selection and evaluation of studies, assessing the risk of bias (with the RoB2, ROBINS-I, QUADAS and Newcastle-Ottawa instruments); 4) qualitative and/or quantitative synthesis (meta-analysis) of the main outcome measures; 5) classification of the quality of the evidence available for each clinical question, which entailed issuing an overall rating for the quality of the data on the outcomes relevant to the question, and 6) development of recommendations, if the evidence allowed, taking into account the GRADE criteria (quality of evidence, values and preferences, balance of benefits, harms and risks, equity and feasibility). 2

We present the summary of the available evidence and related recommendations in tables focused on epidemiology (Table 1) , clinical characteristics (Table 2) , diagnostic tests (Table 3) , treatment (Table 4 ), prevention (Table 5 ) and vaccination (Table 6 ).

Most of the published studies on the transmission of SARS-CoV-2 are observational and use different variables and assessment criteria, which did not allow a meta-analysis of the results. The available reviews are mostly narrative, and while there are a few systematic reviews (SRs), due to the characteristics of the studies that they included we did not believe it would be useful to analyse them in greater detail.

Although the infectious period seems to range from 2 days before the onset of symptoms to 8-10 days after (the pattern in asymptomatic individuals seems to be similar, but it is not well known), a some studies have demonstrated that 44% of contagions occur while the primary case is asymptomatic. 4 Different authors have found substantial variability in the transmission of SARS-CoV-2 depending on the context. 5 The evidence shows that 10% to 20% of primary cases are responsible for 80% of secondary cases. There are probably factors at play in transmission other than viral load. Transmission within the household is 10 times more frequent than outside the household.

International epidemiological data and 1 SR have found a risk of secondary transmission in the population aged under 22 years that is 44% lower compared to the adult population. Children are rarely the index case in their families or the cause of outbreaks. 6 According to the World Health Organization (WHO), COVID-19 is often more severe in people who are older than 60 years or who have health conditions like high blood pressure, cardiovascular or lung problems, diabetes, obesity or cancer, although individuals of any age may develop severe COVID-19 or die from it.

We searched the literature for data on the risk of developing disease of any severity. The data were obtained from observational studies with a high risk of bias and a low or very low quality of evidence (Table 1) . 7 The only risk factor that seems supported by evidence of moderate quality is social inequity, which is measured through different indicators and that is significantly correlated to the incidence and mortality of COVID- 19. 8 In conclusion, although any unvaccinated individual is at risk of being infected, older individuals and individuals with underlying disease are at higher risk of severe COVID-19. The risk of transmission seems higher in adults, elderly individuals in residential facilities, household members of diseased individuals with a dry cough and groups of lower socioeconomic status. Weather and geographical factors may also play a role. C l i n i c a l p i c t u r e Given the heterogeneity of the selected studies, we made a qualitative synthesis of their results but not a meta-analysis. Table 2 presents the most relevant findings.

We included case series describing at least 10 microbiologically confirmed cases and data on symptoms, as well as SRs including studies of these characteristics. Due to the scarcity of neonatal data, we made an exception and included one SR that analysed isolated case reports and small case series. 9 We excluded all the primary sources already included in the selected SRs and sources describing patients that were very likely to be included in larger case series. Most studies had a retrospective observational design and had been conducted in hospital settings (inpatient and emergency care) in the early months of the pandemic. These SRs also had methodological flaws and included heterogeneous results. There was a high risk of bias in all, tending to the underrepresentation of asymptomatic patients and overestimation of the severity of symptoms. Early in the pandemic, tests for microbiological confirmation were ordered nearly exclusively in patients with fever, respiratory symptoms or significant comorbidities, which may have resulted in overestimation of these features. We obtained likelihood ratios for the presence of specific symptoms and a positive reverse-transcriptase polymerase chain reaction (RT-PCR) test for SARS-CoV-2 from a study of greater quality conducted in the community in Canada that included 2463 cases diagnosed between April and September 2020. The best predictor was the combination of 3 symptoms: anosmia/ageusia, nausea/vomiting and headache. 10 When it comes to the risk of hospitalization, the data are imprecise, probably due to the absence of uniform criteria for hospital admission and selection biases in different studies. The most consistent risk factors were age less than 1 year, especially age less than 3 months, preterm birth and certain underlying diseases. 11, 12 The results of different studies regarding the risk of admission to the intensive care unit (ICU) were heterogeneous, and the most consistent factors were age less than 1 month and elevation of Creactive protein.

We collected data on the multisystem inflammatory syndrome in children (MIS-C) 13 from studies that included patients with this particular diagnosis, but the data from all other complications was obtained from general studies on the clinical features of SARS-CoV-2 infection. It is possible that instances of these variables were not documented in primary sources, even if they were actually present. Neurologic complications were analysed in a SR of data obtained from studies on the overall clinical presentation and course of the disease (not focused specifically on neurologic features). 14 D i a g n o s t i c t e s t s In the early months of the COVID-19 pandemic, the ability to diagnose the disease accurately was of critical importance, so numerous studies analysed the different available RT-PCR techniques. In the months that followed, new diagnostic needs emerged, such as improving the turnaround time of tests, the availability of tests for screening and to conduct population seroprevalence studies or reducing the costs of testing, which resulted in the publication of many works focused on the validity of different types of samples and rapid PCR, antigen and antibody tests.

To establish the gold standard, we analysed data from studies on the correlation and the limits of detection of different RT-PCR tests, 15 which were in vitro studies with an appropriate methodological design. When it came to rapid PCR and antigen tests, we searched for studies on their validity and accuracy, most of which, be it individual studies or studies included in metaanalyses, were limited on account of their design and methodology, especially in relation to the inclusion criteria and the reference standard. 16 Furthermore, few studies included children and, when they did, their representation was all but negligible. We analysed one study on the validity of antigen tests focused exclusively on the paediatric population, with results that we considered of moderate-to-low quality due to low precision.

To evaluate the usefulness of quantitative SARS-CoV-2 antibody tests, we analysed data from 4 studies, one of which was a review included in a clinical practice guideline. 17 All recommendations on the subject are based on evidence of very low quality, as most of the sources were case-control studies with a high risk of bias. The findings of the studies, including those included in metaanalyses, were heterogeneous, and there was little agreement in the definition of key concepts, such as the time elapsed from the onset of symptoms. On the other hand, since most of the studies analysed were conducted on the adult population, the evidence is also indirect.

Once the diagnosis has been established, the evidence in adults shows that certain clinical, laboratory or radiological characteristics may support the diagnosis or have prognostic value. The studies we included in the analysis to determine the indication of blood tests, 18 chest radiograph, chest computed tomography 19 or ultrasound 20 in the paediatric population were observational studies with small samples and of very low quality. It is possible that new studies on the subject may improve the quality of the evidence, although we doubt that it will change the direction of the current recommendations (Table 3) .

T r e a t m e n t Since the beginning of the pandemic caused by the novel coronavirus, the global scientific community has made an immense effort to determine which treatments are most appropriate. Still, the experimental evidence in the paediatric population is scarce. The searches we performed did not yield any paediatric randomised controlled trials (RCTs) for the treatments included in the analysis. For this reason, we selected RCTs in adults and paediatric studies irrespective of study design. The main treatment options considered in the analysis were hydroxychloroquine, 21 steroid therapy, 22 tocilizumab, 23 hyperimmune plasma, 24 immunoglobulin therapy and remdesivir. 25 For each treatment, we performed a quantitative synthesis of critical outcome measures, mainly mortality, the most important outcome, and the need of mechanical ventilation. We also estimated other outcomes for some of the treatments, such as survival times or radiological progression.

We were unable to pool the data on the adverse effects of treatment due to differences in reporting between trials, although the safety profile of some of these drugs had already been established (hydroxychloroquine/steroids). Some of the evaluated treatments are not widely accessible (high cost and long duration of treatment), which results in an unfavourable cost-benefit ratio (tocilizumab).

Overall, the quality of the evidence was considered moderate for some treatments, due to inconsistencies, or in some cases low to very low, due to lack of precision and methodological limitations (remdesivir). We only found evidence to support the use of steroid therapy, and evidence against the use of all other treatments. We expect that as new studies are published, the estimated efficacy of some of these treatments will change and may require reconsidering the current recommendations ( Table 4 ).

The evidence on COVID-19 in the paediatric population and specifically on paediatric patients with MIS-C 26 came from observational studies, which outlined a series of therapeutic interventions the efficacy of which cannot be established at present. It seems reasonable to recommend that most paediatric patients with COVID-19 that are asymptomatic or have mild symptoms receive any necessary supportive care. Pharmacological treatment should be reserved for severe cases (chiefly manifesting with MIS-C). In the case of MIS-C, the evidence supports a weak recommendation of combined therapy with intravenous immunoglobulin and methylprednisolone.

P r e ve n t i o n Ma s k s Physical measures are currently the cornerstone of prevention of COVID-19 in the paediatric population. The evidence on the effectiveness of masks is scarce and usually refers to the use of surgical masks, FFP2 masks or equivalent. We did not find any studies devoted exclusively to the paediatric population, although children were included in some of the studies conducted in the community. The evidence on the effectiveness of masks for prevention of COVID-19 is equally poor, as most studies were conducted before the pandemic and focused on other respiratory viruses (influenza, SARS, MERS). Lastly, results regarding their effectiveness vary based on the study design: while clinical trials have not found evidence of effectiveness, 27 observational studies have found an important protective effect. 28 The low quality of the evidence does not allow drawing firm conclusions (Table 5 ). When it comes to safety, there have been no reports of significant adverse events.

Ve r t i c a l t r a n s m i s s i o n , b r e a s t f e e d i n g a n d p r e ve n t i ve m e a s u r es To date, there is no evidence of SARS-CoV-2 vertical transmission to newborns. The conclusions are based on observational studies of moderate-to-low quality that differed in terms of the samples, methods and timing of testing. In nearly all studies, vertical transmission was an infrequent and uncertain event. 29 We found no differences in transmission based on the type of delivery (vaginal/caesarean). There is no evidence that SARS-CoV-2 can be transmitted through breast milk, and there have been no differences in the reported positivity rate between breastfeed and formulafed newborns. 30 Where the newborn stays in hospital during the postpartum period, either roomingin with the mother or separated from the mother, does not have an impact on the risk of neonatal infection.

Studies on the closure of schools published early in the pandemic based their predictions on the behaviour of other viruses, to which we must add the difficulty of isolating the effect of closing schools from the effects of all other nonpharmacological hygiene and social distancing measures that were implemented more or less simultaneously. 31 Some of the most recent studies analyse outcomes based on the level of community transmission of the virus, 32 and therefore recommendations could change during incidence peaks in the community. As is the case of any public health measure, when it comes to making recommendations, it is necessary to take into account all the costs and benefits to society of closing schools and childcare centres.

The publication of the findings of ongoing trials of the different vaccines that are being investigated has been spotty; for some vaccines, data have been published and kept the community abreast of developments in research, whereas for other vaccines no data have been published to date. [33] [34] [35] [36] In the European Union, 4 vaccines against COVID-19 had been authorised as of March 11, 2021: Comirnaty (Pfizer-BioNTech), the Moderna COVID-19 vaccine, the AstraZeneca COVID-19 vaccine and the Jannsen COVID-19 vaccine. At the time of this writing (April 23, 2021), there are data on the efficacy of 2 nonreplicating vaccines based on recombinant viral vectors and 2 vaccines based on messenger RNA, which is greater than 60% in all. This document does not include an assessment of the Janssen vaccine because data from clinical trials is not yet available.

The effectiveness data published to date are encouraging. 37 In Spain, there is evidence of a decrease in the incidence of COVID-19 in nursing homes for the elderly, which were a priority group in the vaccination drive.

As occurs with other RNA viruses, there may be variants of SARS-CoV-2 that escape neutralization by antibodies, As of March 11, there are 3 variants of concern: B. In the overall population (all age groups) worldwide, the seroprevalence of SARS-CoV-2 is 5.3% (95% CI, 4.2%-6.4%).

In the paediatric population (birth-18 years) the seroprevalence of SARS-CoV-2 is 1.56% (95% CI, 0%-3.12%).

In the overall population (all age groups) worldwide, the incidence of symptomatic COVID-19 is of 1437/100 000 inhabitants. Low

In the paediatric population (birth-18 years), the incidence of symptomatic COVID-19 corresponds to 0.8%-2.1% of total cases. Moderate

The cumulative mortality associated with COVID-19 worldwide is of 31.90 per 100 000 inhabitants.

The mortality associated with COVID-19 in Spain is of 146.40/100 000 inhabitants.

The overall fatality rate of COVID-19 worldwide is: case fatality rate, 2.22%; infection fatality rate, 0.68% (95% CI, 0.53%-0.82%).

The overall fatality rate of COVID-19 in Spain is: case fatality rate, 2.16%; infection fatality rate, 1.1% (95% CI, 1.0%-1.2%).

The global paediatric mortality rate associated with COVID-19 is of less than 0.08%. High

The paediatric mortality rate COVID-19 in children aged < 14 years in Spain is of 0.042/100 000 inhabitants. Case fatality rate, 0.0094%.

Low SARS-CoV-2 is mainly transmitted through respiratory droplets (>100 m).

Aerosol transmission of SARS-CoV-2 (<100 m) occurs mainly in closed spaces. Low

Transmission through fomites or physical contact is unlikely. Low

The infectious period usually starts 2 days before the onset of symptoms and lasts for as long as 10 days. It is longer in patients with severe disease (only if symptoms persist). Low

The infectious period of asymptomatic individuals is unknown. This is why control of cases and contacts alone is less effective and why it is very important to maintain social distancing measures. Low

The impact of pollution on SARS-CoV-2 transmission is questionable and the evidence on the subject is from studies with a high probability of bias .

The upper respiratory tract viral load seems to be lower in the population under 20 years . Dyspnoea or breathing difficulty at onset is a risk factor for development of ARDS and for requiring respiratory support. Low

The most frequent manifestations of MIS-C are fever (≥ 38 C) and gastrointestinal symptoms (in 84%: abdominal pain, vomiting or diarrhoea). Low blood pressure is found in nearly 50% and shock in 38%. Respiratory symptoms are less frequent. Low

Patients with MIS-C may develop right ventricular dysfunction (35%), coronary artery dilation/aneurysms (21%) and myocarditis (17%). Moderate 13% of children with MIS-C meet the criteria for complete KD. The presence of at least some of the manifestations of KD is frequent, mainly cutaneous and mucosal manifestations (conjunctival injection, changes in the lips, oedema/erythema/desquamation in hands or feet). Low Compared to classic KD, patients with MIS-C tend to be a little older and are more likely to exhibit echocardiographic abnormalities and certain laboratory abnormalities (hyponatraemia, thrombocytopenia and lymphocytopenia ). Low

Compared to paediatric patients with COVID-19 that do not have MIS-C, patients with MIS-C are more likely to be obese, of a race/ethnicity other than white/European and older. They also have higher levels of acute phase reactants and more severe cytopenias and are more likely to require admission to the ICU, inotropic support and mechanical ventilation. Low

Thromboembolic disease is a rare complication in the paediatric population (1-4/100 patients in series of symptomatic patients, most frequently hospitalised). Low

The literature on neurologic complications is scarce. In patients with severe disease, the incidence of seizures is estimated at approximately 3% and the incidence of encephalitis at about 12%. Low

The mortality in paediatric patients with COVID-19 is of 413/100 000 in hospitalised patients and, in series that also included patients that were not admitted to hospital, of 104-208/100 000. Most deaths result from complications of severe chronic diseases and a direct causal relationship with COVID-19 has yet to be established. Low

There have been isolated reports of paediatric patients with symptoms that persist months after the acute phase of disease ("long COVID"). The most frequently described long COVID symptoms are chest pain, dyspnoea, fatigue, gastrointestinal symptoms, bone or muscle pain and neuropsychiatric symptoms.

There has been an increase in the frequency of caesarean deliveries and preterm births (<37 weeks' gestation) associated with maternal COVID-19. It is unclear whether this increase is due to a greater degree of obstetric intervention with the aim of reducing potential risks for the mother or newborn. Low

Asymptomatic infections in the neonatal period are more frequent than symptomatic infections. When symptoms develop, they tend to be mild and are usually respiratory symptoms (tachypnoea, rhinitis), fever and feeding difficulties.

aOR, adjusted odds ratio; ARDS, acute respiratory distress syndrome; CRP, C-reactive protein; ICU, intensive care unit; LR+, positive likelihood ratio; KD, Kawasaki disease; MIS-C, multisystemic inflammatory syndrome in children associated with SARS-CoV-2. 

The rapid antigen test should be considered as a screening test in patients with compatible symptoms of less than 5 days' duration, and an RT-PCR test should be performed in case of a negative result and persistence of suspicion.

Very low In general, detection of antibodies in any serologic test is considered highly specific. The diagnostic yield of serologic tests improves when they are performed approximately 14 days after the onset of symptoms.

Weak in support Performance of serologic tests is only recommended starting from 14 days after onset of symptoms, so these tests are of little value to diagnose acute disease.

Very low

Of all the available methods, CLIA and ELISA perform better in terms of sensitivity, and CLIA is considered slightly better than ELISA.

Weak in support Performance of CLIA and ELISA is recommended, as they offer a greater sensitivity compared to LFIA, and CLIA performs slightly better than ELISA.

When it comes to the type of immunoglobulin, IgA tests offer a lower specificity. 

Use of tocilizumab is not recommended in paediatric patients with COVID-19.

There is indirect evidence of low quality that hyperimmune plasma does not reduce mortality and of very low quality that it does not decrease the duration of survival. There is no experimental evidence on the efficacy of immunoglobulin therapy.

Use of hyperimmune plasma is not recommended in paediatric patients with COVID-19.

Very low There is no evidence on the efficacy of different treatments used for management of patients with MIS-C associated with SARS-CoV-2 infection.

Observational studies suggests that the combination of intravenous immunoglobulin and methylprednisolone may be more effective than the isolated use of intravenous immunoglobulin.

Contemplate use of intravenous immunoglobulin combined with methylprednisolone for treatment of MIS-C associated with infection by SARS-CoV-2.

Very low There is indirect evidence of very low quality, due to methodological limitations or lack of precision, that does not support the efficacy of other treatments under study. Favourable outcomes have only been observed with remdesivir and calcifediol. The evidence remdesivir is unclear and hints at a possible reduction in mortality but not in the need of mechanical ventilation. Further research should be conducted on the use of calcifediol before making general recommendations for its use in clinical practice.

There is no evidence to support recommendations regarding the use of remdesivir or calcifediol in patients with COVID-19.

Use of other drugs is not recommended: ritonavir/lopinavir, favipiravir, umifenovir, alpha-lipoic acid, baloxavir marboxil, bavirin, interferon alpha, ruxolitinib, colchicine, febuxostat, marboxil, azvudine, leflunomide, ribavirin.

MIS-C, multisystemic inflammatory syndrome in children associated with SARS-CoV-2. 

Vertical transmission of SARS-CoV-2 is very rare, and it has not been possible to establish the timing of transmission (intrauterine, intrapartum or postnatal).

There is no difference in the SARS-CoV-2 infection status of newborns delivered vaginally versus those delivered by caesarean section.

Strong in support Taking into account the costs and benefits, the lack of evidence on the advantages of caesarean delivery and the preference of families, it is recommended that the decision whether to have a caesarean or vaginal delivery be made based on obstetric criteria and not seeking to modify the risk of transmission.

The scarce evidence available does not suggest that SARS-CoV-2 is transmitted through breast milk.

Strong in support The promotion and maintenance of breastfeeding in newborns of mothers with SARS-CoV-2 infection is strongly recommended. Use of preventive measures in the perinatal period to prevent transmission of SARS-CoV-2 to the newborn Very low The scarce evidence available does not allow estimation of the efficacy of preventive measures meant to reduce transmission of SARS-CoV-2 to newborns.

Weak in support Taking into account the costs and benefits, the lack of evidence on the advantages and safety of not implementing preventive measures and the preference of families, in the case of SARS-CoV-2-positive mothers, contemplate maintaining the routine preventive measures that are currently recommended: rooming-in keeping a safe distance except when the infant is being breastfed, handwashing, and use of face masks while the mother remains infectious.

There is evidence of low quality that schools are not an important source of transmission and there is no certainty that their closure would decrease the incidence of disease in the general population or in the population under 18 years, or that it would have a significant impact on the percentage of severe cases (requiring ICU admission) or overall mortality due to COVID-19.

Weak against Closure of schools and childcare centres as a preventive measure to decrease the incidence and severity of COVID-19 in the general population is not recommended.

CI, confidence interval; RR, relative risk; WHO, World Health Organization. The vaccines have shown an efficacy for prevention of severe COVID-19 of nearly 100%.

The current evidence on the prevention of asymptomatic COVID-19 and transmission of SARS-CoV-2 infection is insufficient.

J o u r n a l P r e -p r o o f

The current evidence of the efficacy and safety data in individuals aged more than 60 years is not sufficiently robust, but they do not seem to be lesser compared to younger individuals. There are no data on the immunogenicity or safety of these vaccines in children

The duration of the immunity induced by vaccination against SARS-CoV-2 is not known.

There is evidence that the vaccines are safe and may cause adverse effects, usually mild or moderate, without significant differences between vaccinated individuals and controls. There is no safety data for children.

There is no evidence comparing post-authorization vaccination schedules, so the administration of vaccines should adhere to the directions given in the corresponding summary of product characteristics. Groups that should be vaccinated against SARS-CoV-2

Ideally, every individual in the population should be vaccinated with one of the available COVID-19 vaccines. General recommendation Strong in support Administration of the vaccines available at any given time or place following the recommendations and priorities established by the competent health authorities is recommended.

Manual para la elaboración de Guías de Práctica Clínica en el Sistema Nacional de Salud

Actualización del Manual Metodológico

GRADE handbook for grading quality of evidence and strength of recommendations

Grupo de Trabajo de Pediatría Basada en la Evidencia de la AEP y AEPAP. COVID-19 en Pediatría: valoración crítica de la evidencia

Temporal dynamics in viral shedding and transmissibility of COVID-19

Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: A systematic review and meta-analysis

Children are unlikely to be the main drivers of the COVID-19 pandemic -A systematic review

Retrospective study identifies infection related risk factors in close contacts during COVID-19 epidemic

Association of Social and Demographic Factors With COVID-19 Incidence and Death Rates in the US

Synthesis and systematic review of reported neonatal SARS-CoV-2 infections

Symptoms associated with a positive result for a swab for SARS-CoV-2 infection among children in Alberta

Disease Severity Risk Factors for Pediatric Patients in Italy

Risk Factors for Severe COVID-19 in Children

Associated Multisystem Inflammatory Syndrome in Children -United States

Neurological Complications of SARS-CoV-2 Infection in Children: A Systematic Review and Meta-Analysis

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection

Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19:Serologic Testing

Laboratory abnormalities in children with mild and severe coronavirus disease 2019 (COVID-19): A pooled analysis and review

Collaborators of the European Society of Paediatric Radiology Cardiothoracic Imaging Taskforce

COVID-19) in children: a systematic review of imaging findings

Lung ultrasound in children with COVID-19

Hydroxychloroquine for treatment of nonsevere COVID-19 patients: Systematic review and meta-analysis of controlled clinical trials

Association between Administration of Systemic Corticosteroids and Mortality among Critically Ill Patients with COVID-19: A Meta-analysis

Additional information on the evidence for tocilizumab as a treatment for COVID-19

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev

Drug treatments for covid-19: Living systematic review and network meta-Analysis

Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain

Physical interventions to interrupt or reduce the spread of respiratory viruses. Part 1 -Face masks, eye protection and person distancing: systematic review and meta-analysis. Cochrane Database Syst Rev

Physical distancing, facemasks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis

Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis

Maternal transmission of SARS-COV-2 to the neonate, and possible routes for such transmission: a systematic review and critical analysis

Association between Statewide School Closure and COVID-19 Incidence and Mortality in the US

The Effects of School Reopenings on COVID-19

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Singledose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Vaccine in a Nationwide Mass Vaccination Setting